BR112012026244A2 - uso de um composto, métodos para tratar ou aliviar os sintomas da asma e de doença pulmonar obstrutiva crônica, e para reduzir a incidência de agravamentos ou prevenir agravamentos das asma e de doença pulmonar obstrutiva crônica, composto, e, combinação farmacêutica - Google Patents
uso de um composto, métodos para tratar ou aliviar os sintomas da asma e de doença pulmonar obstrutiva crônica, e para reduzir a incidência de agravamentos ou prevenir agravamentos das asma e de doença pulmonar obstrutiva crônica, composto, e, combinação farmacêuticaInfo
- Publication number
- BR112012026244A2 BR112012026244A2 BR112012026244A BR112012026244A BR112012026244A2 BR 112012026244 A2 BR112012026244 A2 BR 112012026244A2 BR 112012026244 A BR112012026244 A BR 112012026244A BR 112012026244 A BR112012026244 A BR 112012026244A BR 112012026244 A2 BR112012026244 A2 BR 112012026244A2
- Authority
- BR
- Brazil
- Prior art keywords
- asthma
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- compound
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title abstract 5
- 208000006673 asthma Diseases 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000024891 symptom Diseases 0.000 title abstract 3
- 230000004199 lung function Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010901601A AU2010901601A0 (en) | 2010-04-15 | Compound for the treatment of respiratory condition or disease | |
| PCT/AU2011/000434 WO2011127538A1 (en) | 2010-04-15 | 2011-04-14 | Compound for treatment of respiratory condition or disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012026244A2 true BR112012026244A2 (pt) | 2016-07-12 |
Family
ID=44788654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012026244A BR112012026244A2 (pt) | 2010-04-15 | 2011-04-14 | uso de um composto, métodos para tratar ou aliviar os sintomas da asma e de doença pulmonar obstrutiva crônica, e para reduzir a incidência de agravamentos ou prevenir agravamentos das asma e de doença pulmonar obstrutiva crônica, composto, e, combinação farmacêutica |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110257192A1 (https=) |
| EP (1) | EP2558097B1 (https=) |
| JP (1) | JP6148618B2 (https=) |
| KR (1) | KR20130106267A (https=) |
| CN (2) | CN105560245A (https=) |
| AU (1) | AU2011241478B2 (https=) |
| BR (1) | BR112012026244A2 (https=) |
| CA (1) | CA2796207A1 (https=) |
| EA (1) | EA025224B1 (https=) |
| ES (1) | ES2647223T3 (https=) |
| IL (1) | IL222244A0 (https=) |
| MX (1) | MX2012011938A (https=) |
| NZ (1) | NZ603040A (https=) |
| SG (2) | SG184430A1 (https=) |
| WO (1) | WO2011127538A1 (https=) |
| ZA (1) | ZA201207696B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201802648SA (en) | 2013-04-12 | 2018-05-30 | Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
| EA201692549A1 (ru) * | 2014-06-20 | 2017-08-31 | Эвайраджен Терепьютикс, Инк. | Безводная кристаллическая форма свободного основания 6-{2-[1-(6-метил-3-пиридазинил)-4-пиперидинил]этокси}-3-этокси-1,2-бензизоксазола |
| WO2024192151A2 (en) * | 2023-03-13 | 2024-09-19 | Altesa BioSciences, Inc. | Method of dosing vapendavir to treat enterovirus infections |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR213700A0 (en) * | 2000-12-18 | 2001-01-25 | Biota Scientific Management Pty Ltd | Antiviral agents |
| AU2003215246A1 (en) * | 2002-02-14 | 2003-09-04 | Viropharma Incorporated | Methods of reducing rhinovirus contagion and related compositions |
| WO2004073710A1 (en) * | 2003-02-21 | 2004-09-02 | Apodemus Ab | Treatment of diseases caused by ljungan virus by using pleconaril |
| US9308199B2 (en) * | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
| WO2006029182A2 (en) * | 2004-09-07 | 2006-03-16 | The La Jolla Institute For Molecular Medicine | Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases |
| AR057623A1 (es) * | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| CA2725618C (en) * | 2008-05-27 | 2016-04-12 | Biota Scientific Management Pty Ltd | Antiviral salts |
| TW201016215A (en) * | 2008-07-17 | 2010-05-01 | Schering Corp | Compositions and uses of antiviral active pharmaceutical agents |
-
2011
- 2011-04-14 NZ NZ60304011A patent/NZ603040A/en not_active IP Right Cessation
- 2011-04-14 EP EP11768285.6A patent/EP2558097B1/en not_active Not-in-force
- 2011-04-14 BR BR112012026244A patent/BR112012026244A2/pt not_active IP Right Cessation
- 2011-04-14 CA CA2796207A patent/CA2796207A1/en not_active Abandoned
- 2011-04-14 EA EA201201416A patent/EA025224B1/ru not_active IP Right Cessation
- 2011-04-14 KR KR1020127029232A patent/KR20130106267A/ko not_active Ceased
- 2011-04-14 CN CN201510982692.9A patent/CN105560245A/zh active Pending
- 2011-04-14 AU AU2011241478A patent/AU2011241478B2/en not_active Ceased
- 2011-04-14 JP JP2013504064A patent/JP6148618B2/ja active Active
- 2011-04-14 MX MX2012011938A patent/MX2012011938A/es not_active Application Discontinuation
- 2011-04-14 CN CN2011800192025A patent/CN102844032A/zh active Pending
- 2011-04-14 SG SG2012073565A patent/SG184430A1/en unknown
- 2011-04-14 ES ES11768285.6T patent/ES2647223T3/es active Active
- 2011-04-14 WO PCT/AU2011/000434 patent/WO2011127538A1/en not_active Ceased
- 2011-04-14 SG SG10201502391WA patent/SG10201502391WA/en unknown
- 2011-04-15 US US13/087,624 patent/US20110257192A1/en not_active Abandoned
-
2012
- 2012-10-09 IL IL222244A patent/IL222244A0/en unknown
- 2012-10-12 ZA ZA2012/07696A patent/ZA201207696B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013523844A (ja) | 2013-06-17 |
| EA201201416A1 (ru) | 2013-03-29 |
| EP2558097A4 (en) | 2013-09-11 |
| ES2647223T3 (es) | 2017-12-20 |
| KR20130106267A (ko) | 2013-09-27 |
| SG10201502391WA (en) | 2015-05-28 |
| IL222244A0 (en) | 2012-12-31 |
| WO2011127538A1 (en) | 2011-10-20 |
| NZ603040A (en) | 2015-03-27 |
| AU2011241478A1 (en) | 2012-11-01 |
| SG184430A1 (en) | 2012-11-29 |
| EP2558097A1 (en) | 2013-02-20 |
| US20110257192A1 (en) | 2011-10-20 |
| JP6148618B2 (ja) | 2017-06-14 |
| ZA201207696B (en) | 2014-03-26 |
| MX2012011938A (es) | 2013-01-28 |
| EA025224B1 (ru) | 2016-12-30 |
| EP2558097B1 (en) | 2017-10-25 |
| CA2796207A1 (en) | 2011-10-20 |
| CN102844032A (zh) | 2012-12-26 |
| AU2011241478B2 (en) | 2016-12-01 |
| CN105560245A (zh) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015012312A2 (pt) | método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito | |
| ZA201906427B (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition | |
| IL272314A (en) | Use of inhaled nitric oxide for the treatment of pulmonary hypertension associated with lung disease | |
| BR112013001119A2 (pt) | composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas | |
| GT201500218A (es) | Compuesto | |
| BRPI1008227A8 (pt) | composição de glicocorticoide inalável para uso na terapia de um paciente que sofre de asma severa e sem controle. | |
| LT3439660T (lt) | Pimobendano panaudojimas širdies padidėjimo mažinimui bei klinikinių simptomų pasireiškimo atidėjimui pacientams su besimptomiu širdies nepakankamumu dėl mitralinio vožtuvo ligos | |
| BR112013029672A2 (pt) | uso de inibição da catepsina k para o tratamento e/ou profilaxia da hipertensão pulmonar e/ou insuficiência cardíaca | |
| CL2014003286A1 (es) | Composicion farmaceutica en forma de polvo seco que comprende abediterol; y su uso para el tratamiento de una enfermedad respiratoria seleccionada de asma y enfermedad pulmonar obstructiva cronica. | |
| BR112012026244A2 (pt) | uso de um composto, métodos para tratar ou aliviar os sintomas da asma e de doença pulmonar obstrutiva crônica, e para reduzir a incidência de agravamentos ou prevenir agravamentos das asma e de doença pulmonar obstrutiva crônica, composto, e, combinação farmacêutica | |
| IL242143B (en) | A pharmaceutical preparation for oral administration for the prevention or treatment of dry eye syndrome, containing rabamifid or its prodrug | |
| BR112016008082A2 (pt) | métodos para tratamento de doença pulmonar obstrutiva crônica usando benralizumab | |
| EP2120935A4 (en) | NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA | |
| BR112012032766A2 (pt) | uso de antagonistas do receptor de adenosina a2b para o tratamento da hipertensão pulmonar | |
| BR112013024525A2 (pt) | compostos, composição farmacêutica e métodos para tratar condição pré-cancerosa ou câncer em mamífero, pacientes com doença inflamatória crônica ou doença neurodegenerativa e para preparar compostos e usos de compostos e de composição farmacêutica | |
| BR112015025438A2 (pt) | silicato de zircónio e diuréticos microporosa para a redução de potássio e de tratamento renal crônico e / ou doença cardíaca crônica | |
| CL2013002325A1 (es) | Compuestos derivados de 4-amino-2-butenamidas, inhibidores de catepsina c; composicion farmaceutica que los comprende; procedimiento de preparacion de la composicion farmaceutica; uso del compuesto en el tratamiento de enfermedad pulmonar obstructiva cronica. | |
| EP2125728A4 (en) | NOVEL COMBINATION OF COMPOUNDS FOR THE TREATMENT OF AIRWAY DISEASES, IN PARTICULAR CHRONIC OBSTRUCTIVE BRONCHOPNEUMOPATHY (COPD) AND ASTHMA | |
| BR112012030362A2 (pt) | tomilho/onagra ou hera para o tratamento de enfermidades pulmonares obstrutivas crônicas (epoc) | |
| PT2931275T (pt) | Aclidínio para usar no aumento da atividade física na vida diária de um doente que sofre de doença pulmonar obstrutiva crónica | |
| BR112015004810A2 (pt) | preparações de tiotrópio | |
| WO2013188016A3 (en) | Surfactant therapy for exposure to ionizing radiation | |
| Gon et al. | Carbocisteine attenuates influenza virus A replication in the bronchoalveolar lavage fluids of virus-infected mice | |
| 徐金敏 | The change of cystatine C in Parkinson's disease patients with obstructive sleep ayndrome | |
| Shen et al. | Follow-up of chronic filariasis patients in Jinshan District, Shanghai from 2009 to 2011 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |